|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: TNNT2 |
Gene summary for TNNT2 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | TNNT2 | Gene ID | 7139 |
| Gene name | troponin T2, cardiac type | |
| Gene Alias | CMD1D | |
| Cytomap | 1q32.1 | |
| Gene Type | protein-coding | GO ID | GO:0003007 | UniProtAcc | P45379 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 7139 | TNNT2 | C08 | Human | Oral cavity | OSCC | 6.57e-11 | 2.20e-01 | 0.1919 |
| 7139 | TNNT2 | SYSMH5 | Human | Oral cavity | OSCC | 2.09e-05 | 1.57e+00 | 0.0647 |
| Page: 1 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Oral Cavity |  | EOLP: Erosive Oral lichen planus |
| LP: leukoplakia | ||
| NEOLP: Non-erosive oral lichen planus | ||
| OSCC: Oral squamous cell carcinoma |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:003238615 | Oral cavity | OSCC | regulation of intracellular transport | 218/7305 | 337/18723 | 6.91e-22 | 1.41e-19 | 218 |
| GO:000701520 | Oral cavity | OSCC | actin filament organization | 230/7305 | 442/18723 | 1.37e-08 | 2.77e-07 | 230 |
| GO:003297020 | Oral cavity | OSCC | regulation of actin filament-based process | 209/7305 | 397/18723 | 1.89e-08 | 3.72e-07 | 209 |
| GO:001003820 | Oral cavity | OSCC | response to metal ion | 188/7305 | 373/18723 | 4.34e-06 | 5.00e-05 | 188 |
| GO:005134618 | Oral cavity | OSCC | negative regulation of hydrolase activity | 182/7305 | 379/18723 | 1.98e-04 | 1.32e-03 | 182 |
| GO:00605378 | Oral cavity | OSCC | muscle tissue development | 185/7305 | 403/18723 | 2.60e-03 | 1.14e-02 | 185 |
| GO:00327815 | Oral cavity | OSCC | positive regulation of ATPase activity | 18/7305 | 27/18723 | 3.34e-03 | 1.42e-02 | 18 |
| GO:00426927 | Oral cavity | OSCC | muscle cell differentiation | 175/7305 | 384/18723 | 4.79e-03 | 1.92e-02 | 175 |
| GO:00434626 | Oral cavity | OSCC | regulation of ATPase activity | 27/7305 | 46/18723 | 5.33e-03 | 2.07e-02 | 27 |
| GO:00147067 | Oral cavity | OSCC | striated muscle tissue development | 174/7305 | 384/18723 | 6.45e-03 | 2.40e-02 | 174 |
| GO:003103217 | Oral cavity | OSCC | actomyosin structure organization | 93/7305 | 196/18723 | 9.63e-03 | 3.41e-02 | 93 |
| GO:0051764 | Oral cavity | OSCC | actin crosslink formation | 10/7305 | 14/18723 | 1.44e-02 | 4.69e-02 | 10 |
| Page: 1 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| TNNT2 | SNV | Missense_Mutation | c.155N>A | p.Arg52Lys | p.R52K | P45379 | protein_coding | tolerated(0.81) | benign(0) | TCGA-3C-AALI-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unspecific | Poly E | Complete Response | |
| TNNT2 | SNV | Missense_Mutation | c.419N>A | p.Arg140His | p.R140H | P45379 | protein_coding | deleterious(0) | probably_damaging(0.996) | TCGA-D8-A1Y2-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | tamoxiphen | SD | |
| TNNT2 | SNV | Missense_Mutation | rs730881123 | c.472N>T | p.Arg158Trp | p.R158W | P45379 | protein_coding | deleterious(0) | probably_damaging(0.999) | TCGA-DS-A0VK-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | carboplatin | PD |
| TNNT2 | SNV | Missense_Mutation | c.259C>T | p.Pro87Ser | p.P87S | P45379 | protein_coding | deleterious(0.01) | probably_damaging(0.99) | TCGA-Q1-A73P-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD | |
| TNNT2 | SNV | Missense_Mutation | rs121964856 | c.305G>T | p.Arg102Leu | p.R102L | P45379 | protein_coding | deleterious(0) | probably_damaging(0.988) | TCGA-AA-3864-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | SD |
| TNNT2 | SNV | Missense_Mutation | novel | c.326T>C | p.Leu109Pro | p.L109P | P45379 | protein_coding | deleterious(0) | probably_damaging(0.996) | TCGA-AD-6964-01 | Colorectum | colon adenocarcinoma | Male | <65 | III/IV | Chemotherapy | folfox | PD |
| TNNT2 | SNV | Missense_Mutation | c.284T>A | p.Val95Glu | p.V95E | P45379 | protein_coding | deleterious(0) | probably_damaging(0.982) | TCGA-CM-6162-01 | Colorectum | colon adenocarcinoma | Female | <65 | III/IV | Chemotherapy | oxaliplatin | SD | |
| TNNT2 | SNV | Missense_Mutation | rs730881123 | c.472C>T | p.Arg158Trp | p.R158W | P45379 | protein_coding | deleterious(0) | probably_damaging(0.999) | TCGA-G4-6304-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Chemotherapy | fluorouracil | PD |
| TNNT2 | SNV | Missense_Mutation | rs397516465 | c.445N>T | p.Arg149Cys | p.R149C | P45379 | protein_coding | deleterious(0.04) | probably_damaging(0.996) | TCGA-QG-A5Z2-01 | Colorectum | colon adenocarcinoma | Male | <65 | I/II | Unknown | Unknown | SD |
| TNNT2 | SNV | Missense_Mutation | rs757664792 | c.865N>A | p.Gly289Arg | p.G289R | P45379 | protein_coding | deleterious(0) | probably_damaging(0.999) | TCGA-A5-A0G1-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| Page: 1 2 3 4 5 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| 7139 | TNNT2 | DRUGGABLE GENOME | PYROGALLOL RED | PYROGALLOL RED | ||
| 7139 | TNNT2 | DRUGGABLE GENOME | PURPUROGALLIN | PURPUROGALLIN | ||
| 7139 | TNNT2 | DRUGGABLE GENOME | TIRAMSETIV | |||
| 7139 | TNNT2 | DRUGGABLE GENOME | NSC-107022 | CHEMBL1601846 |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |